--- title: "Novavax, Inc. (NASDAQ:NVAX) Receives Consensus Rating of \"Hold\" from Brokerages" description: "Novavax, Inc. (NASDAQ:NVAX) has received a consensus rating of \"Hold\" from nine research firms. The recommendations include four sell, one hold, and four buy ratings. The average price target is $11.2" type: "news" locale: "en" url: "https://longbridge.com/en/news/276528095.md" published_at: "2026-02-22T06:15:05.000Z" --- # Novavax, Inc. (NASDAQ:NVAX) Receives Consensus Rating of "Hold" from Brokerages > Novavax, Inc. (NASDAQ:NVAX) has received a consensus rating of "Hold" from nine research firms. The recommendations include four sell, one hold, and four buy ratings. The average price target is $11.25. Recent target price adjustments include JPMorgan lowering it to $6.00 and TD Cowen to $7.00, while B. Riley maintains a buy rating with a target of $16.00. Institutional investors hold 53.04% of the stock, which opened at $9.20, with a market cap of $1.50 billion and a PE ratio of 5.14. Novavax, Inc. (NASDAQ:NVAX - Get Free Report) has been assigned an average recommendation of "Hold" from the nine research firms that are currently covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $11.25. - Analysts Think These Stocks Could More Than Double in Value Several equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. dropped their target price on shares of Novavax from $7.00 to $6.00 and set an "underweight" rating on the stock in a report on Tuesday, November 18th. TD Cowen dropped their price target on Novavax from $8.00 to $7.00 and set a "hold" rating on the stock in a research note on Tuesday, November 4th. B. Riley Financial reaffirmed a "buy" rating and issued a $16.00 price objective (down previously from $18.00) on shares of Novavax in a report on Monday, November 10th. BTIG Research reissued a "buy" rating and issued a $19.00 target price on shares of Novavax in a report on Tuesday, January 20th. Finally, Wall Street Zen cut Novavax from a "hold" rating to a "sell" rating in a research report on Saturday, January 31st. **View Our Latest Research Report on NVAX** ## Institutional Trading of Novavax - Is Biotech’s Bull Run Over? Examining Election Impacts Several large investors have recently added to or reduced their stakes in the business. Quarry LP purchased a new stake in Novavax during the third quarter valued at approximately $33,000. Flagship Harbor Advisors LLC bought a new stake in shares of Novavax during the 4th quarter valued at $33,000. Danske Bank A S purchased a new stake in shares of Novavax in the 3rd quarter worth $64,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Novavax by 25.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,896 shares of the biopharmaceutical company's stock worth $53,000 after purchasing an additional 1,617 shares in the last quarter. Finally, State of Wyoming bought a new position in Novavax in the 2nd quarter worth $52,000. 53.04% of the stock is currently owned by institutional investors. ## Novavax Price Performance Shares of Novavax stock opened at $9.20 on Friday. The company has a current ratio of 2.27, a quick ratio of 2.24 and a debt-to-equity ratio of 5.93. The firm has a market capitalization of $1.50 billion, a PE ratio of 5.14 and a beta of 2.58. The business's 50-day moving average price is $8.01 and its 200-day moving average price is $7.97. Novavax has a 12 month low of $5.01 and a 12 month high of $10.64. ## Novavax Company Profile (Get Free Report) - Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze? Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses. The company's lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus. ## Featured Stories - Five stocks we like better than Novavax - Elon Musk already made me a “wealthy man” - America’s 1776 happening again - \[How To\] Invest Pre-IPO In SpaceX With $100! - How a Family Trust May Be Able To Help Preserve Your Wealth - Elon Musk: This Could Turn $100 into $100,000 *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Novavax Right Now? Before you consider Novavax, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novavax wasn't on the list. While Novavax currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md) - [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md) - [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md) - [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md) - [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/en/quote/IBBQ.US.md) - [NVAX.US - Novavax](https://longbridge.com/en/quote/NVAX.US.md) - [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Pacific Biosciences 的高管出售股票以履行税务义务 | 太平洋生物科学公司（Pacific Biosciences）总裁兼首席执行官 Christian O. Henry 于 2026 年 2 月 17 日和 18 日出售了 472,667 股普通股，以支付与限制性股票单位相关的税务义务。这些交 | [Link](https://longbridge.com/en/news/276400839.md) | | 阿伯丁集团有限公司在 Tectonic Therapeutic, Inc. $TECX 中建立了价值 559 万美元的头寸 | 阿伯丁集团（Aberdeen Group plc）在 Tectonic Therapeutic, Inc.（纳斯达克代码：TECX）中获得了约 559 万美元的新头寸，在第三季度购买了 356,176 股。这项投资约占 Tectonic 股 | [Link](https://longbridge.com/en/news/276507461.md) | | Assetmark Inc. 出售了 18,236 股硕腾公司（Zoetis Inc.）的股票，股票代码为$ZTS | Assetmark Inc. 在第三季度将其在 Zoetis Inc. (NYSE:ZTS) 的持股减少了 69.1%，出售了 18,236 股，剩余 8,173 股，市值为 1,196,000 美元。其他机构投资者也调整了他们的持股。分析 | [Link](https://longbridge.com/en/news/276508320.md) | | Intellia Therapeutics (NTLA) 预计将在周四宣布季度财报 | Intellia Therapeutics（纳斯达克代码：NTLA）将于 2026 年 2 月 26 日市场开盘前公布其 2025 年第四季度财报。分析师预测每股亏损 0.99 美元，收入为 1217 万美元。该股票开盘价为 12.48 美 | [Link](https://longbridge.com/en/news/276312151.md) | | Tempus AI 执行副总裁 Erik Phelps 出售了部分股份 | 埃里克·菲尔普斯（Erik Phelps），Tempus AI 的执行副总裁兼首席行政官，于 2026 年 2 月 19 日出售了 9,464 股 A 类普通股，总金额为 562,472 美元。此次销售包括 3,814 股，每股售价为 60 | [Link](https://longbridge.com/en/news/276495655.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.